BGS vs. BIOG, HNE, CTUK, AAIF, LWI, GRID, CTPE, JAGI, SST, and HINT
Should you be buying Baillie Gifford Shin Nippon stock or one of its competitors? The main competitors of Baillie Gifford Shin Nippon include The Biotech Growth Trust (BIOG), Henderson EuroTrust (HNE), CT UK Capital And Income Investment Trust (CTUK), abrdn Asian Income Fund (AAIF), Lowland Investment (LWI), Gresham House Energy Storage (GRID), CT Private Equity Trust (CTPE), JPMorgan Asia Growth & Income (JAGI), Scottish Oriental Smaller Cos (SST), and Henderson International Income Trust (HINT). These companies are all part of the "asset management" industry.
Baillie Gifford Shin Nippon (LON:BGS) and The Biotech Growth Trust (LON:BIOG) are both small-cap financial services companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, community ranking, institutional ownership, profitability and dividends.
Baillie Gifford Shin Nippon received 21 more outperform votes than The Biotech Growth Trust when rated by MarketBeat users. However, 64.06% of users gave The Biotech Growth Trust an outperform vote while only 62.05% of users gave Baillie Gifford Shin Nippon an outperform vote.
Baillie Gifford Shin Nippon's return on equity of -16.33% beat The Biotech Growth Trust's return on equity.
Baillie Gifford Shin Nippon has higher earnings, but lower revenue than The Biotech Growth Trust. Baillie Gifford Shin Nippon is trading at a lower price-to-earnings ratio than The Biotech Growth Trust, indicating that it is currently the more affordable of the two stocks.
Baillie Gifford Shin Nippon has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500. Comparatively, The Biotech Growth Trust has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500.
32.4% of Baillie Gifford Shin Nippon shares are held by institutional investors. Comparatively, 26.7% of The Biotech Growth Trust shares are held by institutional investors. 0.3% of Baillie Gifford Shin Nippon shares are held by insiders. Comparatively, 0.5% of The Biotech Growth Trust shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
In the previous week, Baillie Gifford Shin Nippon had 1 more articles in the media than The Biotech Growth Trust. MarketBeat recorded 2 mentions for Baillie Gifford Shin Nippon and 1 mentions for The Biotech Growth Trust. The Biotech Growth Trust's average media sentiment score of 0.76 beat Baillie Gifford Shin Nippon's score of 0.30 indicating that The Biotech Growth Trust is being referred to more favorably in the news media.
Summary
Baillie Gifford Shin Nippon beats The Biotech Growth Trust on 9 of the 14 factors compared between the two stocks.
Get Baillie Gifford Shin Nippon News Delivered to You Automatically
Sign up to receive the latest news and ratings for BGS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Baillie Gifford Shin Nippon Competitors List
Related Companies and Tools
